Phase 2 Study of Melphalan/HDS and Tebentafusp for Metastatic Uveal Melanoma
This Phase 2 study is testing a combination of two treatments, Melphalan/HDS (given through a liver procedure called percutaneous hepatic perfusion, or PHP) followed by Tebentafusp (given intravenously), for people with metastatic uveal melanoma that has spread to the liver. The goal is to see how well this combination works and if it's safe. You might be able to join if you are at least 18 years old, have uveal melanoma that has spread to your liver, and have a specific genetic marker called HLA-A*02:01. The main way researchers will measure success is by looking at how long people live without their cancer growing or spreading (Progression Free Survival) for up to 24 months. The study plans to enroll 18 participants, but its current recruitment status is unclear.
- Study design
- This is a Phase 2 interventional study planning to enroll 18 participants. It evaluates the efficacy and safety of sequential treatment with Melphalan/HDS via PHP followed by Tebentafusp.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed to measure Progression Free Survival for up to 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07276386
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Recruiting
PHASE2Ages 18+InterventionalTreatmentH. Lee Moffitt Cancer Center and Research InstituteInvestigator-initiated
~18 participants
Updated 2026-03-31 on ClinicalTrials.gov
What's tested:Melphalan/HDS (Percutaneous Hepatic Perfusion)Tebentafusp
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression Free Survival (PFS)
Measured over Up to 24 months
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Jonathan Zager, MD, FACS · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patient is ≥18 years of age on the day of signing informed consent.
ECOG performance status of 0 or 1.
Histologically or cytologically confirmed liver metastasis of uveal melanoma.
HLA-A\*02:01 positive status.
Measurable disease by computed tomography (CT) per RECIST 1.1 with at least one target lesion identified in the liver.
Patient deemed suitable for PHP and tebentafusp.
Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female patients of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 150 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Limited extrahepatic disease would be allowed initially, that can be treated with stereotactic body radiation therapy (SBRT) or surgical resection prior to the start of tebentafusp. This concept is similar to the FOCUS trial - definition of "treatable" limited disease at the discretion of the PI.
Ability to provide and understand written informed consent prior to any study procedures.
History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), significant arrhythmias and severe valvular disease that precludes the use of general anesthesia.
History or evidence of clinically significant pulmonary disease e.g. severe COPD that precludes the use of general anesthesia.
Patients who are unable to undergo general anesthesia for any reason.
Reduced renal function defined as Serum Creatinine \>=1.5xULN or Creatinine Clearance \< 40 mL/min, calculated using the Cockcroft and Gault formula.
Reduced hepatic function (defined as AST, ALT, bilirubin\>2.5\*ULN and PT-INR\>1.5) or medical history of liver cirrhosis (Child-Pugh Class B or C) or evidence of portal hypertension by history, endoscopy or radiology.
Hemoglobin \<90 g/L or platelets \<100x109/L or neutrophils \<1.5x109/L.
Use of live vaccines four weeks before the last study treatment.
History of severe reactions to melphalan, heparin or iodine contrast. Iodine contrast reaction history patients permitted if patient will be treated with pre-meds, or if still problematic, treating physician may switch to MRI TAP.
Known human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C.
Active autoimmune disease or a documented history of autoimmune disease requiring active systemic immunosuppressive treatment. Type-1 diabetes, atopic dermatitis, and hypothyroidism are exceptions to this.
A condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications (other than physiologic (i.e., \>10 mg) doses of steroids or as specified in exclusion #14) or use of other investigational drugs.
Has a known additional malignancy that is progressing or requires active treatment.
Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of study drug.
A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate in the opinion of the treating investigator.
Previous treatment with PHP or tebentafusp.
Exclusion
Life expectancy of less than 6 months.
More than 50% of the liver volume replaced by tumor as measured by MRI.
What this trial measures
- Progression Free Survival (PFS)Up to 24 months
PFS will be studied as time-to-event defined by the first documented disease progression or death due to any cause, whichever occurs first, from the start date of the study treatment. PFS will be determined based on tumor assessment (RECIST version 1.1 criteria).